Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 835

1.

The impact of systematic retroperitoneal lymphadenectomy on long-term oncologic outcome of women with advanced ovarian clear-cell carcinoma.

Kajiyama H, Suzuki S, Yoshikawa N, Tamauchi S, Shibata K, Kikkawa F.

J Gynecol Oncol. 2020 Jan 8. doi: 10.3802/jgo.2020.31.e47. [Epub ahead of print]

2.

SURF4 maintains stem-like properties via BIRC3 in ovarian cancer cells.

Yue Y, Xia L, Xu S, Wang C, Wang X, Lu W, Xie X.

J Gynecol Oncol. 2020 Jan 21. doi: 10.3802/jgo.2020.31.e46. [Epub ahead of print]

3.
4.

Comparing efficacy of high-dose rate brachytherapy versus helical tomotherapy in the treatment of cervical cancer.

Kim S, Lee S, Hong JH, Park YJ, Song JY, Lee JK, Lee NW.

J Gynecol Oncol. 2019 Dec 20. doi: 10.3802/jgo.2020.31.e42. [Epub ahead of print]

5.

The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy.

Wu X, Qin J, Shen T, Fei W, Chen L, Xie X, Lu W.

J Gynecol Oncol. 2020 Jan 7. doi: 10.3802/jgo.2020.31.e36. [Epub ahead of print]

6.

Risk factors for early death among ovarian cancer patients: a nationwide cohort study.

Mosgaard BJ, Meaidi A, Høgdall C, Noer MC.

J Gynecol Oncol. 2019 Dec 19. doi: 10.3802/jgo.2020.31.e30. [Epub ahead of print]

7.

Safety evaluation of abdominal trachelectomy in patients with cervical tumors ≥2 cm: a single-institution, retrospective analysis.

Okugawa K, Yahata H, Sonoda K, Ohgami T, Yasunaga M, Kaneki E, Kato K.

J Gynecol Oncol. 2019 Dec 18. doi: 10.3802/jgo.2020.31.e41. [Epub ahead of print]

8.

Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma.

Xiang M, Kidd EA.

J Gynecol Oncol. 2019 Dec 6. doi: 10.3802/jgo.2020.31.e39. [Epub ahead of print]

9.

Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor.

Kim H, Park W, Kim YS, Kim YJ.

J Gynecol Oncol. 2019 Nov 21. doi: 10.3802/jgo.2020.31.e35. [Epub ahead of print]

10.

Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer.

Tate S, Nishikimi K, Kato K, Matsuoka A, Kambe M, Kiyokawa T, Shozu M.

J Gynecol Oncol. 2019 Dec 9. doi: 10.3802/jgo.2020.31.e34. [Epub ahead of print]

11.

Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition.

Wang E, Sorolla A.

J Gynecol Oncol. 2019 Nov 5. doi: 10.3802/jgo.2020.31.e29. [Epub ahead of print]

12.

Quantitative analysis of proteins related to chemoresistance to paclitaxel and carboplatin in human SiHa cervical cancer cells via iTRAQ.

He Y, Han SB, Geng YN, Yang SL, Wu YM.

J Gynecol Oncol. 2019 Nov 7. doi: 10.3802/jgo.2020.31.e28. [Epub ahead of print]

13.

Prognostic significance of lymphovascular space invasion in patients with endometrioid endometrial cancer: a retrospective study from a single center.

Dai Y, Dong Y, Cheng Y, Hou H, Wang J, Wang Z, Wang J.

J Gynecol Oncol. 2019 Nov 28. doi: 10.3802/jgo.2020.31.e27. [Epub ahead of print]

14.

Primary sarcoma of the cervix: an analysis of patient and tumor characteristics, treatment patterns, and outcomes.

Albert A, Lee A, Allbright R, Vijayakumar S.

J Gynecol Oncol. 2019 Oct 23. doi: 10.3802/jgo.2020.31.e25. [Epub ahead of print]

15.

BRCA1/2 mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling.

Chao A, Lin YH, Yang LY, Wu RC, Chang WY, Chang PY, Chang SC, Lin CY, Huang HJ, Lin CT, Chou HH, Huang KG, Kuo WL, Chang TC, Lai CH.

J Gynecol Oncol. 2019 Oct 25. doi: 10.3802/jgo.2020.31.e24. [Epub ahead of print]

16.

Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer.

Kim YN, Lee YJ, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.

J Gynecol Oncol. 2020 Mar;31(2):e23. doi: 10.3802/jgo.2020.31.e23. Epub 2019 Oct 22.

18.

Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: a systematic review and meta-analysis.

Sabeena S, Kuriakose S, Damodaran B, Ravishankar N, Arunkumar G.

J Gynecol Oncol. 2020 Mar;31(2):e20. doi: 10.3802/jgo.2020.31.e20. Epub 2019 Oct 22.

19.

Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma.

Iijima M, Okonogi N, Nakajima NI, Morokoshi Y, Kanda H, Yamada T, Kobayashi Y, Banno K, Wakatsuki M, Yamada S, Kamada T, Aoki D, Hasegawa S.

J Gynecol Oncol. 2020 Mar;31(2):e19. doi: 10.3802/jgo.2020.31.e19. Epub 2019 Sep 26.

20.

Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery.

Yang J, Yang J, Cao D, Shen K, Ma J, Zhang F.

J Gynecol Oncol. 2020 Mar;31(2):e16. doi: 10.3802/jgo.2020.31.e16. Epub 2019 Sep 17.

Supplemental Content

Loading ...
Support Center